Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Change in Acquisitions & Divestments: 2022-2025

Historic Change in Acquisitions & Divestments for Corvus Pharmaceuticals (CRVS) over the last 4 years, with Sep 2025 value amounting to $28.5 million.

  • Corvus Pharmaceuticals' Change in Acquisitions & Divestments rose 90.89% to $28.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $74.1 million, marking a year-over-year increase of 97.73%. This contributed to the annual value of $42.6 million for FY2024, which is 31.93% down from last year.
  • As of Q3 2025, Corvus Pharmaceuticals' Change in Acquisitions & Divestments stood at $28.5 million, which was up 47.93% from $19.3 million recorded in Q2 2025.
  • Corvus Pharmaceuticals' Change in Acquisitions & Divestments' 5-year high stood at $28.5 million during Q3 2025, with a 5-year trough of $810,000 in Q1 2022.
  • In the last 3 years, Corvus Pharmaceuticals' Change in Acquisitions & Divestments had a median value of $14.9 million in 2024 and averaged $15.0 million.
  • Per our database at Business Quant, Corvus Pharmaceuticals' Change in Acquisitions & Divestments spiked by 2,088.27% in 2023 and then tumbled by 73.93% in 2024.
  • Quarterly analysis of 4 years shows Corvus Pharmaceuticals' Change in Acquisitions & Divestments stood at $15.4 million in 2022, then tumbled by 40.85% to $9.1 million in 2023, then surged by 56.73% to $14.3 million in 2024, then skyrocketed by 90.89% to $28.5 million in 2025.
  • Its Change in Acquisitions & Divestments stands at $28.5 million for Q3 2025, versus $19.3 million for Q2 2025 and $12.0 million for Q1 2025.